BBCvsXBIETF Comparison
VS
Virtus LifeSci Biotech Clinical Trials ETF (BBC) belongs to the Tomorrow's Treatments segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. BBC's top 1 sector exposures are Healthcare. In contrast, XBI's top sector exposures are Healthcare and Finance. BBC is more expensive with a Total Expense Ratio (TER) of 0.65%, versus 0.35% for XBI. BBC is up 27.77% year-to-date (YTD) with +$5M in YTD flows. XBI performs better with 28.16% YTD performance, and +$399M in YTD flows. Run a side-by-side ETF comparison of BBC and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBC vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/11/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBC XBI | -5.78%-1.19% | +17.22%+17.80% | +27.77%+28.16% | +102.82%+63.89% | +137.50%+99.44% | +6.45%+19.93% |
| Flows | BBC XBI | --$106M | +$83K+$806M | +$5M+$399M | +$12M+$1.18B | +$16M-$537M | +$8M+$1.48B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBC XBI | +33.39%+29.24% | +36.22%+27.93% | +37.22%+28.27% | +39.64%+32.91% |
| Max drawdown | BBC XBI | -11.65%-10.46% | -14.64%-10.46% | -54.25%-32.94% | -70.43%-53.28% |
| Max drawdown duration | BBC XBI | 23d40d | 60d40d | 340d331d | 1666d1622d |
Trading data
BBC | XBI | |
Last sale 9/11/2026 at 1:30 PM | $49.39 | $156.20 |
| Previous close 09/10/2026 | $49.91 | $156.82 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
BBC | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
BBC | XBI | |
|---|---|---|
| Last price | $49.39 | $156.20 |
| 1D performance | -1.05% | -0.40% |
| AuM | $46.95 M | $10.37 B |
| E/R | 0.65% | 0.35% |
Characteristics
BBC | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | VIRTUS Investment Partners | State Street Investment Management |
| Benchmark | LifeSci Biotechnology Clinical Trials Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 127 | 149 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 2014 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBC
USA
86.49%
Other
13.51%
XBI
USA
95.3%
Other
4.7%
Sectors
BBC
Healthcare
95.06%
Other
4.94%
XBI
Healthcare
99.41%
Other
0.59%
Advertisement
Diversification
BBC
Total weight of top 15 holdings out of 15
15.32%
XBI
Total weight of top 15 holdings out of 15
20.29%
Top 15 holdings
Data as of July 31, 2026
BBC
First Tracks Biotherapeutics, Inc.
1.57%
Monopar Therapeutics, Inc.
1.22%
MBX Biosciences, Inc.
1.14%
Zenas BioPharma, Inc.
1.09%
Xencor, Inc.
1.06%
Apogee Therapeutics, Inc.
1.00%
REGENXBIO, Inc.
0.96%
Oric Pharmaceuticals, Inc.
0.96%
Dyne Therapeutics, Inc.
0.93%
uniQure NV
0.91%
SELLAS Life Sciences Group, Inc.
0.91%
Nurix Therapeutics, Inc.
0.91%
Vor Biopharma, Inc.
0.89%
Erasca, Inc.
0.89%
Amylyx Pharmaceuticals, Inc.
0.88%
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
Frequently asked questions about BBC and XBI
How have the BBC and XBI ETFs performed in 2026?
As of September 11, 2026, BBC is up 27.77% year-to-date (YTD), while XBI has returned 28.16%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: BBC or XBI?
Year-to-date, the BBC ETF saw +$5M in flows, compared to +$399M for XBI.
Which ETF is more volatile: BBC or XBI?
Over the past year, BBC had a volatility of 36.22%, while XBI experienced 27.93%.
Which ETF is bigger: BBC or XBI?
As of September 11, 2026, BBC holds $46.95 M in assets under management (AUM), while XBI manages $10.37 B.
What sectors do the BBC and XBI ETFs invest in?
BBC leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the BBC ETF and XBI ETF?
BBC top holdings include First Tracks Biotherapeutics, Inc., Monopar Therapeutics, Inc. and MBX Biosciences, Inc.. XBI holds in its top three: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc..
Which ETF is more diversified: BBC or XBI?
BBC holds 127 securities with 15.32% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 20.29%.
Advertisement
Latest news about BBC & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
BBC
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
